Journals / Viral Hepatitis Journal / 2019 / Cilt: 25 - Sayı: 2

Relationship Between Basic Laboratory Results and Fibrosis in Chronic Hepatitis B Patients

Kronik Hepatit B Hastalarında Temel Laboratuvar Sonuçları ile Fibrozis Arasındaki İlişki

Pages
45–49
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Doctors who follow up chronic hepatitis B patients should be carefully evaluate these parameters when giving LB decision.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Liver biopsy (LB) is an important cornerstone in decision to start treatment for chronic hepatitis B (HB).
📊
Key Findings & Data:According to study protocol, necroinflammatory scores ≤4 and fibrosis scores ≤1 were accepted as normal liver (NL), and the high value in one of these scores was accepted as chronic hepatitis (CH).Results: A total of 234 patient’s LBs included in the study.
💡
Conclusion & Impact:Doctors who follow up chronic hepatitis B patients should be carefully evaluate these parameters when giving LB decision.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Liver biopsy (LB) is an important cornerstone in decision to start treatment for chronic hepatitis B (HB). Viral load and liver function tests are performed to determine the most appropriate time. In this study, factors affecting liver fibrosis in hepatitis B e antigen (HBeAg) negative chronic hepatitis B patients were investigated.Materials and Methods: LB and the other laboratory results such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), and hepatitis B virus (HBV)-DNA were collected from patient files, retrospectively. According to study protocol, necroinflammatory scores ≤4 and fibrosis scores ≤1 were accepted as normal liver (NL), and the high value in one of these scores was accepted as chronic hepatitis (CH).Results: A total of 234 patient’s LBs included in the study. A total of 74 (31.6%) patients’ LB was evaluated as NL. In univariate analysis, age, gender, ALT, AST, GGT, AFP and HBV-DNA >100.000 IU/mL, and in multivariate analysis, age, AST level >29 U/L, and AFP level >2.5 ng/mL were the independent risk factors for CH.Conclusion: According to our results, age, AST and AFP predict CH. Doctors who follow up chronic hepatitis B patients should be carefully evaluate these parameters when giving LB decision.

Özet

Amaç: Kronik hepatit B tedavisine başlama kararını vermede karaciğer biyopsisi önemli bir mihenk taşıdır. Uygun zamanı belirlemek için viral yük ve karaciğer fonksiyon testleri ile takip yapılmaktadır. Bu çalışmada hepatit B e antigen (HBeAg) negatif kronik hepatit B hastalarında karaciğer fibrozisini etkileyen faktörler araştırıldı. Gereç ve Yöntemler: Karaciğer biyopsisi ve alanin aminotransferaz (ALT), aspartat aminotransferaz (AST), gama-glutamil transpeptidaz (GGT) ve hepatit B virüs (HBV)-DNA gibi laboratuvar testleri geriye dönük olarak hasta dosyalarından toplandı. Çalışma protokolüne göre nekroenflamatuvar skor ≤4 ve fibrozis skoru ≤1 tespit edilenler normal karaciğer (NK), bu skorlardan birindeki yüksek değer kronik hepatit (KH) olarak kabul edildi. Bulgular: Çalışmaya toplam 234 hastanın karaciğer biyopsisi dahil edildi. Toplam 74 (%31,6) hastanın biyopsi sonucu NK olarak kabul edildi. Tek değişkenli analizlerde yaş, cinsiyet, ALT, AST, GGT, AFP ve HBV-DNA >100,000 IU/mL düzeyi NK ve KH arasında istatistiksel olarak farklıydı. Çok değişkenli analizlerde ise yaş, AST >29 U/L ve AFP >2,5 ng/mL düzeyi KH için bağımsız risk faktörüydü. Sonuç: Sonuçlarımıza göre, yaş, AST ve AFP, KH’yi öngörmektedir. Kronik hepatit B hastalarını izleyen doktorlar, karaciğer biyopsisi kararı alırken bu parametreleri dikkatli bir şekilde değerlendirmelidir.

🔖

Cite This Article

KARABAY, O., KÖSEM, M., GÜÇLÜ, E., ÖĞÜTLÜ, A., ERKORKMAZ, Ü. (2022). Relationship Between Basic Laboratory Results and Fibrosis in Chronic Hepatitis B Patients. Viral Hepatitis Journal, Cilt: 25 - Sayı: 2, 45–49. https://ajindex.com/articles/646368

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398
  2. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-1026
  3. Özkan H. Epidemiology of Chronic Hepatitis B in Turkey. Euroasian J Hepatogastroenterol. 2018;8:73-74
  4. Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun Huang. Comparison of histologic characteristics of Chinese chronic hepatitis B Patients with persistently normal or mildly elevated ALT. PLoS One. 2013;8:e80585
  5. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341
  6. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57:196-202
  7. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435
  8. Lala V, Minter DA. Liver Function Tests. 2018 Oct 27. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2018. Available from
  9. Hasanjani Roushan MR, Hajiahmadi M, Shafaie S. Histopathological features of liver and its relation to serum transaminase levels in 91 cases of anti-HBe-positive chronic hepatitis B. Int J Clin Pract. 2005;59:791-794
  10. Office of regulatory affairs, Office of operations. Investigations operation manual 2018. Available from https://www.fda.gov/ downloads/ICECI/Inspections/IOM/UCM607759.pdf 11. Anfuso S, Soncini E, Bonelli P, Piantelli G, Gramellini D. Second-trimester maternal serum alpha-fetoprotein elevation and its association with adverse maternal/fetal outcome: ten years experience. Acta Biomed. 2007;78:214-219
  11. Babalı A, Çakal E, Purnak T, Bıyıkoğlu İ, Çakal B, Yüksel O, Köklü S. Serum α-fetoprotein levels in liver steatosis. Hepatol Int. 2009;3:551-555
  12. Chen CH, Lin ST, K